H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, H.C.
Beam Therapeutics Inc. (BEAM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 9,928,111 | $193,896,008 | +21% | 1.08% |
| 2. | ARK Investment Management Catherine D. Wood | 8,480,089 | $165,616,138 | +20% | 1.66% |
| 3. | Kynam Capital Derrick Tang | 2,518,170 | $49,179,860 | +44% | 4.13% |
| 4. | Citadel Investment Group Ken Griffin | 2,500,347 | $48,831,777 | +22% | 0.01% |
| 5. | Redmile Group Jeremy Green | 1,610,329 | $31,449,725 | +6% | 2.97% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.12 | 876 | $17,625.12 | 64,864 | 2025-07-03 | Filing | |
| $16.94 | 374 | $6,336.42 | 65,740 | 2025-07-01 | Filing | |
| $18.35 | 5,674 | $104,121.87 | 117,294 | 2025-04-01 | Filing | |
| $18.35 | 30,663 | $562,684.45 | 986,249 | 2025-04-01 | Filing | |
| $18.35 | 7,434 | $136,418.36 | 190,216 | 2025-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,871,292 | $173,256,333 | 0% | |
| 2. | 8,102,656 | $158,244,881 | 0% | |
| 3. | 7,920,053 | $154,678,642 | 0.01% | |
| 4. | 4,540,132 | $88,668,778 | 43% | |
| 5. | 4,266,871 | $83,331,991 | 0.06% |
News See All
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy
Beam Therapeutics Inc. (NASDAQ:BEAM) has secured U.S.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
10 Best Growth Stocks to Invest in for the Next 10 Years
On March 8, Ben Snider, Goldman Sachs senior equity strategist, joined CNBC to discuss the state of the economy today.
10 Best Emerging Technology Stocks to Buy Now
The technology sector is constantly evolving, with emerging technology companies leading the charge in groundbreaking innovations.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
Billionaire Hedge Funds
